Canafarma Hemp Products Corp (CSE:CNFA) has said it is launching three more of its YOOFORIC branded hemp oil-infused chewing gums in August this year, bringing the total number of its gum products to six.
The move comes after news last Monday June 22, that the group is launching two new lines in July this year - YOOFORIC RISE and YOOFORIC PILLOW TALK.
READ: Canafarma Hemp Products to launch two new chewing gums in July
The new gums set for August are YOOFORIC GO, YOOFORIC PRO and YOOFORIC AFTER PARTY. The first two are designed for athletes and golfers respectively.
- YOOFORIC GO combines 5 mg of hemp-sourced CBD per piece with ginseng and caffeine. It also contains magnesium citrate to help reduce fatigue and maximize energy
- YOOFORIC PR0, aimed at golfers, contains naturally occurring CBD, ginseng, caffeine, wild green oat extract, sage and magnesium citrate
- YOOFORIC AFTER PARTY is aimed at 'lessening brain fog, headache, and stomach upset and providing more energy, focus, and joy'
The idea behind infusing gum with CBD is that it increases the bioavailability to the human body because it is chewed in the mouth and absorbed there, bypassing the stomach and liver, preventing degradation by acids and enzymes and first-pass metabolism.
CanaFarma is testing the theory with an ongoing pilot study at Wageningen University and preliminary results are encouraging. After half an hour of chewing, of the original amount of CBD in the gum, 16-24% was retrieved, meaning that 76-84%, of the 10 mg piece of gum was released in the mouth.
"Despite the fact that this percentage is already quite high, it has the potential to be increased when participants are instructed to chew intensively. Furthermore, ongoing development of the gum has shown potential to increase CBD release. The study is scheduled to be completed in August," the firm noted.
There are four pillars to the CanaFarma business - it has a grow operation, a manufacturing component, an extraction facility, and a sales effort, using its direct-to-consumer model.
Contact the author at [email protected]
